1. Delattre JY et al. Distribution of brain metastases. Arch Neurol 1988; 45: 741–4.
2. Patchelly RA et al. A randomised trial of surgery in single brain metastasis to the brain. N Engl J Med 1990; 322: 494–500.
3. Patchelly RA et al. A randomised trial of surgery in single brain metastasis to the brain. N Engl J Med 1990; 322: 494–500.
4. Berk L. An overview of radiotherapy trials for the treatment of brain metastases. Oncology 1995; 9: 1205–12.
5. Glantz et al. Practice parameter: anticonvulsant profilaxis in patients with newly diagnosed brain tumors. Report of the Quality Standarts Subcommittee of the American Academy of Neurology. Neurology 2000; 54: 1886–96.
6. Byrne TN et al. Brain metastases from melanoma. J Neyrooncology 1983; 1: 313–7; Posner JB. Neyrologic complications of cancer. Philadelphia, PH: PA. Davis 1995.
7. Batchelor T et al. Medical management of cerebral metastases. Neuroserg Clin North Am 1996; 7: 435–46.
8. Lesser GJ. Chemotherapy of cerebral metastases from solid tumors. Neurosurg Clin North Am 1996; 7: 527–36.
9. Balch C, Reintgen DS, Kirkwood JM. Cutaneous melanoma.In: De Vita VT Jr, Hellman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology (ed.5). Philadelphia, PA, Lippincott-Raven. 1997; p. 1947–94.
10. DeVita, Cancer, 5-е издание, 1997, Lippincott-Raven.
11. Anderson CM, Buzaid AC, Legha SS. Systemic treatments for advanced cutaneous melanoma. Oncology 1995; 9: 1149–580.
12. Calabresi E, Apro M, Becquatt D et al. Multicenter phase II trial of the single fotemustine in patients with malignant melanoma. Ann Oncol 1991; 2: 377–8.
13. Jacquillat C, Khayat D, Banzet P et al. Final report of the French multicentr phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1999; 66: 1873–8.
14. Avril MF, Boneterre J,Cupissol D et al. Fotemustin plus dacarbasin fore malignant melanoma. E J Cancer 1992; 28A: 1807–11.
15. Daponte A. Cancer 2000.
16. Avril MF, Aamdal S, Grob JJ et al. J Clin Oncol 2004; 22: 1118–25.
17. Константинова М,. Гершанович М.Л., Акимов М.А., Носов Д.А., Богданова Н.В. Открытая, несравнительная, многоцентровая оценка эффективности и безопасности мюстофорана, цисплатина, тамоксифена при лечении диссеминированной меланомы: Результаты Программы IC4-10036-46-RU., 2004.
18. Bernardo G, Palumbo R, Bernardo A et al. A prospective phase II study of single-agent Fotemustine in pretreated advanced malignant melanoma (mm) with or without brain metastases (bm) Ann Oncol 2004; 15 (Suppl. 3): Abstr. 771.
19. Mohr P et al. 9th ICAT, Paris. 1999; 156. Abstract O96.
20. Stevens MFG, Hickman JA, Langdon SP et al. Antitumor activity and pharmacokinetics in mice of S-carbomoyl-2-methylimidazo 5, l-d, 2, 3, 5 – tetrazin-4(3H)-one (CCRG 81045; M Si B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987; 47: 5846–52.
21. Middleton MR, Grob JJ, Aatonson N et al. Randomize phase III study of temozolamide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncl 2000; 18: 158–66.
22. Caraglia M, Addeo R, Costanzo R et al. Italy Pegylated Liposomal Doxorubicin plus Temozolamide is active in the treatment of brain metastases from solid tumours: Ann Oncol 2004; 15 (Suppl. 3): Abst. 792P.
23. Vestermark LW, Larsen S, Lindeloev B, Bastholt L. Phase II study of thalidomide in patients with brain metastases from malignant melanoma. Eur J Cancer Suppl 2005; 3 (2): Abst. 1200: p. 346.
24. Postmus PE et al. A phase III study EORTC. JClin Oncol 2000; 18: 3400–8.
25. Depierre A et al. Evaluetion of topotecan in relapsed small lung cancer. A multicenter phase II study. Lung Cancer 1997; 18 (Suppl. 1): 35.
26. Korfel A et al. Response to topotecan of symptomatic brain metastases of small cell lung cancer also after whole – brain irradiation. Eur J Cancer 2002; 38: 1724–9.
27. Francosi V et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, non-small cell lung cancer or malignant melanoma: a prospective study. Cancer 1999; 85: 1599–605.
28. Wong E et al. The role to topotecan in the treatment of brain metastases. Oncologist 2004; 9: 68–79.
29. Caraglia M, Addeo R, Costanzo R et al. Italy Pegylated Liposomal Doxorubicin plus Temozolamide is active in the treatment of brain metastases from solid tumours: Ann Oncol 2004; 15 (Suppl. 3): Abst. 792P.
30. TsukadaY et al. Fouard A. Pickren JW. Central nervous system metastases from breast carcinoma: autopsy study. Cancer 1983; 52: 2349–54.
31. Lee YT. Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol 1983; 23: 175–80.
32. PatanaphanV et al. Breast cancer: patterns and their prognosis. South Med J 1988; 81: 1109–12.
33. Patanaphan R, Sanz B, Martin R. Arages et al. Biological functions of brain metastasis from breast cancer: Eur J Cancer Suppl 2006; 4 (2): 165.
34. Ryberg M, Langer S, Skovsgaard T et al. Reduction of the incidence of central nervous metastases in patients treated with high dose epirubicin and high dose cyclophosphamide compared to high dose epirubicin alone for metastastic breast cancer. Eur J Cancer Suppl 2003; 1 (5): S140, Abstr. 460.
35. Dawood S, Bismar T, Alcindor T, Muanza T. Clinical and molecular characteristics of breast cancer patients with brain metastasis: a retrospective study. Eur J Cancer 2005; 3 (2): 123, Abstr. 441.
36. Sanna G, Rocca A, Franceschelli L et al. Risk factors for brain metastasis in patients with advanced breast cancer Eur J Cancer Suppl 2005; 3 (2): 128, Abstr. 459.
37. De La Monte et al. Endocrine organ metastases from breast carcinoma Am J Pathol 1984; 114: 131–6.
38. De La Monte et al. Influence of age on the metastatic bechavior of breast carcinoma Hum Pathol 1988; 19: 529–34.
39. Maki et al. Patterns of disease spread in metastatic breast carcinoma: influence of estrogen and progesterone receptor status. Am J Neurorad 2000; 21: 1064–6.
40. Niwinska A, Tacikowska M, Pienkowski T et al. Occult brain metastases in her-2-positive breast cancer patients Eur J Cancer Suppl 2006; 4 (2): 164, Abstr. 396.
41. Chemotherapy induced regression of brain metastases in breast carcinoma. Cancer 1986; 58: 832–9.
42. Siena S et al. Multicenter phase II study of temosolamide therapy for brain metastasis in patients with malignant melanoma, breast cancer and non-small cell lung cancer. Proc ASCO 2003; 22–102.
43. Oberhoff С et al. Topotecan chemotherapy in patients with breast cancer and brein metastases: results of pilot study. Onkologie 2001; 24: 256–60.
44. Loibl S, Schnappauf B, Kumarasamy V et al. Brain metastases in breast cancer. Ann Oncol 2004; 15 (Suppl. 3): Abstr. 118P.
45. Souglakos J, Vamvakas L, Saridaki Z et al. Increase incedence of central nervous system (CNS) involvement for patients with breast cancer (BC) treated with Taxanes based chemotherapy. [114P].
46. Kallioniemi et al. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of viscerak metastasis and poor long-term survival in breast cancer. Int J Cancer 1991; 49: 650–5.
47. Landt S et al. Expression of the growth factor receptors HER2 and EGFR in primary tumors and in brain metastases of breast cancers: Eur J Cancer Suppl 2005; 3 (2): 80, Abstr. 285.
48. Clayton et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004; 91: 639–43.
49. Gori S, Rimondini S, De Angelis V. High incidence of brain metastases in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) treated with trastuzumab and chemotherapy Eur J Cancer Suppl 2005; 3 (2): 115, Abstr. 412.
50. Bendell et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97: 2972–7.
51. Heinrich et al. Proc Am Soc Clin Oncol 2003;
52. Church DN, Modgil R, Guglani S et al. Extended survival in women receiving trastuzumab for brain metastases from HER2 positive metastatic breast cancer. Eur J Cancer Suppl 2006; 4 (2): 163, Abstr. 394.
53. Miller et al. Ann Oncol 2003.
54. Duchnowska R, Czartoryska-Arlukowicz B, Radecka B et al. Brain metastases in HER-2 positive metastatic breast cancer (MBC) patients. Eur J Cancer Suppl 2006; 4 (2): 165, Abstr. 402.
55. Massard C, Brain E, Dunan A. Influence of trastuzumab on the incidence of brain metastasis in patients with Her2-overexpressing metastatic breast cancer. Eur J Cancer Suppl 2005; 3 (2): 119, Abstr. 425.
56. Корытова Л.И. Результаты использования мюстофорана у больных с множественным метастатическим поражением головного мозга, 2005.
57. Loibl S, Schnappauf B, Kumarasamy V et al. Brain metastases in breast cancer. Ann Oncol 2004; 15 (Suppl. 3): Abstr. 118P.
58. Rudnicka H, Niwinska A, Pienkowski T et al. The significance of chemotherapy in the treatment of carcinomatous meningitis in breast cancer patients. Eur J Cancer Suppl 2005; 3 (2): Abstr. 460, Page 129.
59. Niwinska A, Rudnicka H, Giermek J et al. Does systemic chemotherapy improve outcome in breast cancer patients with carcinomatous meningitis? Eur J Cancer Suppl 2 (3): 134, Abstr. 268.

М.М.Константинова

ГУЗ Московский областной онкологический диспансер